Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) just unveiled an announcement.
Shanghai MicroPort MedBot has announced that its core product, the Toumai Laparoscopic Surgical Robot, has surpassed 100 commercial orders worldwide, marking a significant milestone in its commercialization efforts. The company has achieved installations in nearly 80 units globally, with over 15,000 human clinical surgeries performed using Toumai. This expansion includes installations in major hospital systems across multiple continents, highlighting the company’s growing influence in the global high-end medical market.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$35.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a joint stock company based in China, specializing in the development and commercialization of advanced robotic surgical systems. The company focuses on laparoscopic, orthopedic, and vascular interventional products, with a strong market presence both domestically and internationally.
Average Trading Volume: 8,433,438
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.44B
For detailed information about 2252 stock, go to TipRanks’ Stock Analysis page.